{"log_id": 3016266814924184668, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 0, "average": 0.90902, "min": 0.90902}, "location": {"width": 64, "top": 180, "height": 22, "left": 93}, "words": " 300mg"}, {"probability": {"variance": 1e-06, "average": 0.99929, "min": 0.997064}, "location": {"width": 294, "top": 216, "height": 38, "left": 89}, "words": "出现不良反应后剂量的调整"}, {"probability": {"variance": 1.4e-05, "average": 0.998801, "min": 0.976737}, "location": {"width": 922, "top": 249, "height": 52, "left": 137}, "words": "如果接受甲磺酸伊马替尼治疗过程中出现严重非血液学不良反应(如严重水潴留),应停"}, {"probability": {"variance": 2e-06, "average": 0.999302, "min": 0.993147}, "location": {"width": 730, "top": 302, "height": 48, "left": 89}, "words": "药,直到不良反应消失,然后再根据该不良反应的严重程度调整剂量"}, {"probability": {"variance": 0, "average": 0.999497, "min": 0.998858}, "location": {"width": 295, "top": 361, "height": 36, "left": 91}, "words": "严重肝脏毒性时剂量的调整"}, {"probability": {"variance": 0.000163, "average": 0.997178, "min": 0.918816}, "location": {"width": 924, "top": 394, "height": 50, "left": 140}, "words": "如胆红素升高>正常范围上限3倍或转氨酶升高>正常范围上限5倍,宜停止服用甲磺酸"}, {"probability": {"variance": 0.001657, "average": 0.990038, "min": 0.777244}, "location": {"width": 717, "top": 445, "height": 46, "left": 92}, "words": "伊马替尼,直到上述指标分别降到正常范围上限的1.5或2.5倍以下"}, {"probability": {"variance": 9e-06, "average": 0.998526, "min": 0.986816}, "location": {"width": 923, "top": 490, "height": 48, "left": 142}, "words": "以后,甲磺酸伊马替尼治疗可以减量后继续服用。成人每日剂量应该从400mg减少到"}, {"probability": {"variance": 1.7e-05, "average": 0.997279, "min": 0.979868}, "location": {"width": 969, "top": 537, "height": 52, "left": 96}, "words": "300mg,或从600mg减少到400mg或从800mg减少至600mg;儿童和青少年从260mg/m2减"}, {"probability": {"variance": 0.000483, "average": 0.991153, "min": 0.876968}, "location": {"width": 491, "top": 595, "height": 41, "left": 95}, "words": "少到200mg/m2或从340mg/m2减少到260mg/m"}, {"probability": {"variance": 3.8e-05, "average": 0.997634, "min": 0.971735}, "location": {"width": 465, "top": 642, "height": 40, "left": 96}, "words": "中性粒细胞减少或血小板减少时剂量的调整"}, {"probability": {"variance": 0.00421, "average": 0.975905, "min": 0.65829}, "location": {"width": 913, "top": 681, "height": 49, "left": 148}, "words": "P+CML加速期或急变期,Ph+ALL(起始剂量600mg/日,或儿童和青少年340mg/m2日)"}, {"probability": {"variance": 0.000259, "average": 0.993494, "min": 0.919159}, "location": {"width": 970, "top": 729, "height": 49, "left": 97}, "words": "如果出现严重中性粒细胞和血小板减少(中性粒细胞<0.5×10和或血小板<10×10°L),应"}, {"probability": {"variance": 0.000568, "average": 0.994939, "min": 0.845185}, "location": {"width": 972, "top": 777, "height": 51, "left": 96}, "words": "确定是否血细胞减少症与白血病有关(抽取骨髓或活检)。如果血细胞减少症不是由白血病引"}, {"probability": {"variance": 0.001443, "average": 0.988737, "min": 0.782542}, "location": {"width": 949, "top": 827, "height": 50, "left": 98}, "words": "起的,建议剂量减少到400mg/日或儿童和青少年260mg/m2/日。如果血细胞减少持续2周"}, {"probability": {"variance": 0.007122, "average": 0.979355, "min": 0.449514}, "location": {"width": 970, "top": 872, "height": 52, "left": 100}, "words": "则进一步减少剂量至300mg/日或儿童和青少年200mg/m2/日,如血细胞减少持续4周,应停"}, {"probability": {"variance": 0.002967, "average": 0.984552, "min": 0.691928}, "location": {"width": 971, "top": 920, "height": 51, "left": 101}, "words": "药,直到中性粒细胞≥1×10/和血小板≥20×10L。再用时剂量为300mg/日;或儿童和青"}, {"probability": {"variance": 0.000165, "average": 0.992779, "min": 0.957489}, "location": {"width": 182, "top": 987, "height": 29, "left": 103}, "words": "少年200mg/m2/日"}, {"probability": {"variance": 0.001261, "average": 0.985608, "min": 0.792537}, "location": {"width": 921, "top": 1016, "height": 51, "left": 155}, "words": "CML慢性期患者(起始剂量400mg/日或儿童和青少年260mg/m2/日):当中性粒细胞<1.0"}, {"probability": {"variance": 0.021487, "average": 0.930032, "min": 0.428153}, "location": {"width": 963, "top": 1065, "height": 51, "left": 108}, "words": "×10°和或血小板<50×10°时应停药,在中性粒细胞三1.5×10°/L和血小板≥75×10°/L"}, {"probability": {"variance": 0.003156, "average": 0.984511, "min": 0.644961}, "location": {"width": 973, "top": 1112, "height": 54, "left": 104}, "words": "时才应该恢复用药,治疗可恢复为剂量400mg/日或儿童和青少年260mgm2/日。如果再次出"}, {"probability": {"variance": 0.00841, "average": 0.96981, "min": 0.557005}, "location": {"width": 972, "top": 1161, "height": 50, "left": 106}, "words": "现危急数值(中性粒细胞<1.0×10°/L和/或血小板<50×10°/L),治疗中断后的重新治疗剂量减"}, {"probability": {"variance": 0.006056, "average": 0.975809, "min": 0.660684}, "location": {"width": 436, "top": 1219, "height": 42, "left": 108}, "words": "至300mg/日或儿童和青少年200mg/m2/日"}, {"probability": {"variance": 0.014207, "average": 0.965863, "min": 0.435361}, "location": {"width": 378, "top": 1270, "height": 39, "left": 109}, "words": "HESCEL(起始剂量为100mg/日)"}, {"probability": {"variance": 0.009974, "average": 0.967347, "min": 0.459059}, "location": {"width": 923, "top": 1305, "height": 49, "left": 157}, "words": "当中性粒细胞ANC<1.0×10°/L和或血小板<50×10°/时应停药,在中性粒细胞ANC"}, {"probability": {"variance": 0, "average": 0.995783, "min": 0.995783}, "location": {"width": 45, "top": 1225, "height": 134, "left": 1157}, "words": "章"}, {"probability": {"variance": 0.010159, "average": 0.970635, "min": 0.404523}, "location": {"width": 1090, "top": 1353, "height": 51, "left": 112}, "words": "≥1.5×10/L和血小板≥75×10时才应该恢复用药。可以重新用之前的剂量(即发生严重不"}, {"probability": {"variance": 0.006321, "average": 0.975368, "min": 0.700129}, "location": {"width": 303, "top": 1414, "height": 39, "left": 112}, "words": "良事件之前的剂量)开始给药"}, {"probability": {"variance": 0.001814, "average": 0.973585, "min": 0.853485}, "location": {"width": 302, "top": 1463, "height": 38, "left": 116}, "words": "ASM(起始剂量100mg/日):"}, {"probability": {"variance": 0.009675, "average": 0.969578, "min": 0.493256}, "location": {"width": 924, "top": 1496, "height": 52, "left": 161}, "words": "当中性粒细胞ANC<1.0×109/L和或血小板<50×10°时应停药,在中性粒细胞ANC"}], "language": 3}